Kate Yen

Kate Yen is the Founder and CEO of Auron Therapeutics, a biotech company developing next-generation cancer therapies by combining cutting-edge science with AI-powered analysis to map key drivers of tumorigenesis. She earned her Ph.D. in Biological Chemistry from UCLA, where she also completed her postdoc and later served as a professor.

Kate held roles at Merck before joining Agios Pharmaceuticals, where she led translational research for two FDA-approved IDH mutant inhibitors and co-led the discovery of vorasidenib, a glioma therapy now in clinical development.